Antonello Veccia

9PUBLICATIONS
31CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

|Feb 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Antonello Veccia, Ettore D'Argento, Floriana Morgillo

|Jan 28, 2026
Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection-Results of the MEET-URO 22 Study.

Orazio Caffo, Umberto Basso, Antonello Veccia

|Feb 26, 2025
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives.

Antonello Veccia, Mariachiara Dipasquale, Martina Lorenzi

|Nov 27, 2024
Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line.

Antonello Veccia, Mariachiara Dipasquale, Stefania Kinspergher

|Dec 09, 2022
Impact of KRAS Mutations on Clinical Outcomes of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Receiving Anti-PD-1/PD-L1 Therapy.

Antonello Veccia, Mariachiara Dipasquale, Stefania Kinspergher

Pageof 2

Frequent Collaborators

6 joint publications

Orazio Caffo

2 joint publications

Alberto Pavan

1 joint publications

Martina Lorenzi

1 joint publications

Umberto Basso